Skip to main content

Table 4 Prevalence of molecular markers associated with P. falciparum resistance to SP in IPTi intervention and non-intervention zone in Kolokani in December 2007 after one year of implementation.

From: Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali

 

No IPTi

IPTi

OR

95% CI

p

Molecular Markers

n

Prevalence

(95% CI)

n

Prevalence

(95% CI)

   

DHPS 437

432

19.4%

(15.1 - 24.6)

479

21.7%

(17.4-26.7)

1.15

0.59- 2.24

0.68

DHPS 540

428

0.9%

(0.2-3.1)

474

1.0%

(0.3-3.1)

1.13

0.16-7.99

0.90

DHFR 51

379

56.5%

(50.1-62.6)

402

51.0%

(44.9-57.1)

0.80

0.52-1.23

0.32

DHFR 59

376

55.3%

(48.9-61.5)

402

51.0%

(44.9-57.1)

0.84

0.50-1.40

0.51

DHFR 108

375

56.8%

(50.4-63.0)

392

47.7%

(41.5-53.9)

0.69

0.47-1.03

0.07

Triple DHFR mutation

(DHFR 51, 59 and 108)

368

44.8%

(38.5-51.3)

384

38.5%

(32.6-44.8)

0.77

0.50-1.19

0.24

Quadruple mutation (DHFR 51, 59 and 108 + DHPS 437)

367

11.2%

(7.6-16.0)

379

11.6%

(8.1-16.4)

1.04

0.51-2.12

0.90